Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/874 |
| _version_ | 1797571517079355392 |
|---|---|
| author | Antonio Facciorusso Mohamed A Abd El Aziz Siddharth Singh Sara Pusceddu Massimo Milione Luca Giacomelli Rodolfo Sacco |
| author_facet | Antonio Facciorusso Mohamed A Abd El Aziz Siddharth Singh Sara Pusceddu Massimo Milione Luca Giacomelli Rodolfo Sacco |
| author_sort | Antonio Facciorusso |
| collection | DOAJ |
| description | Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of the DerSimonian and Laird test. Primary endpoint was the time-dependent correlation between statin use and HCC incidence expressed as hazard ratio (HR), both crude and adjusted. The crude and adjusted odds ratios (OR) for HCC occurrence between statin users and non-users were analyzed. Twenty-five studies with 1,925,964 patients were included. Crude OR for HCC incidence was 0.59 (95% CI: 0.47–0.74), confirmed in adjusted analysis (OR: 0.74, 95% CI: 0.70–0.78). Adjusted HR was 0.73 (95% CI: 0.69–0.76). This effect was more pronounced in HBV patients (HR: 0.46, 95% CI: 0.36–0.60) and with a cumulative daily dose beyond 365 (HR: 0.27, 95% CI: 0.11–0.67). Lipophilic statins were associated with reduced HCC incidence (HR: 0.49, 95% CI: 0.39–0.62). Atorvastatin determined the greater magnitude of effect (HR: 0.43, 95% CI: 0.28–0.65). This meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins. |
| first_indexed | 2024-03-10T20:42:03Z |
| format | Article |
| id | doaj.art-8176a44f71db4c7cb3b54d3831120272 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:42:03Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8176a44f71db4c7cb3b54d38311202722023-11-19T20:37:53ZengMDPI AGCancers2072-66942020-04-0112487410.3390/cancers12040874Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-AnalysisAntonio Facciorusso0Mohamed A Abd El Aziz1Siddharth Singh2Sara Pusceddu3Massimo Milione4Luca Giacomelli5Rodolfo Sacco6Section of Gastroenterology, Department of Medical Sciences, University of Foggia, 71122 Foggia, ItalyDepartment of Surgery, Mayo Clinic, Rochester, MN 55905, USADivision of Gastroenterology, University of California, San Diego, CA 92093, USAFondazione IRCCS—Istituto Nazionale dei Tumori Via G. Venezian 1 IT, 20133 Milan, ItalyFondazione IRCCS—Istituto Nazionale dei Tumori Via G. Venezian 1 IT, 20133 Milan, ItalyDepartment of Surgical Sciences and Integrated Diagnostics, University of Genoa, 16126 Genoa, ItalySection of Gastroenterology, Department of Medical Sciences, University of Foggia, 71122 Foggia, ItalyStatins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of the DerSimonian and Laird test. Primary endpoint was the time-dependent correlation between statin use and HCC incidence expressed as hazard ratio (HR), both crude and adjusted. The crude and adjusted odds ratios (OR) for HCC occurrence between statin users and non-users were analyzed. Twenty-five studies with 1,925,964 patients were included. Crude OR for HCC incidence was 0.59 (95% CI: 0.47–0.74), confirmed in adjusted analysis (OR: 0.74, 95% CI: 0.70–0.78). Adjusted HR was 0.73 (95% CI: 0.69–0.76). This effect was more pronounced in HBV patients (HR: 0.46, 95% CI: 0.36–0.60) and with a cumulative daily dose beyond 365 (HR: 0.27, 95% CI: 0.11–0.67). Lipophilic statins were associated with reduced HCC incidence (HR: 0.49, 95% CI: 0.39–0.62). Atorvastatin determined the greater magnitude of effect (HR: 0.43, 95% CI: 0.28–0.65). This meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins.https://www.mdpi.com/2072-6694/12/4/874cirrhosisHCCcancerhazard ratiosurvival |
| spellingShingle | Antonio Facciorusso Mohamed A Abd El Aziz Siddharth Singh Sara Pusceddu Massimo Milione Luca Giacomelli Rodolfo Sacco Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis Cancers cirrhosis HCC cancer hazard ratio survival |
| title | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_full | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_fullStr | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_full_unstemmed | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_short | Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis |
| title_sort | statin use decreases the incidence of hepatocellular carcinoma an updated meta analysis |
| topic | cirrhosis HCC cancer hazard ratio survival |
| url | https://www.mdpi.com/2072-6694/12/4/874 |
| work_keys_str_mv | AT antoniofacciorusso statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT mohamedaabdelaziz statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT siddharthsingh statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT sarapusceddu statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT massimomilione statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT lucagiacomelli statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis AT rodolfosacco statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis |